Ironwood Pharmaceuticals Inc. Watch

from 8-K 223 pages Amendment No. 1 to Credit Agreement

from SC TO-C 208 pages Credit Agreement Dated as of May 21, 2023 by and Among Ironwood Pharmaceuticals, Inc., as Borrower Wells Fargo Bank, National Association, as Administrative Agent, and as Collateral Agent Citizens Bank, N.A., as Co-Administrative Agent and the Lenders Party Hereto Citibank, N.A., Citizens Bank, N.A., Jpmorgan Chase Bank, N.A., Rbc Capital Markets, Llc1, and Wells Fargo Securities, LLC as Joint Lead Arrangers and Joint Bookrunners

from 8-K 208 pages Credit Agreement Dated as of May 21, 2023 by and Among Ironwood Pharmaceuticals, Inc., as Borrower Wells Fargo Bank, National Association, as Administrative Agent, and as Collateral Agent Citizens Bank, N.A., as Co-Administrative Agent and the Lenders Party Hereto Citibank, N.A., Citizens Bank, N.A., Jpmorgan Chase Bank, N.A., Rbc Capital Markets, Llc1, and Wells Fargo Securities, LLC as Joint Lead Arrangers and Joint Bookrunners

from 10-K 12 pages Credit Suisse Capital LLC C/O Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, Ny 10010-3629 Date: August 7, 2019 To: Ironwood Pharmaceuticals, Inc. 301 Binney Street Cambridge, Ma 02142 Attn: Chief Legal Officer From: Credit Suisse Capital LLC Subject: Partial Terminations of Relevant Transactions Listed on Attached Schedule a and Related Amendments

from 8-K 7 pages Credit Suisse Capital LLC C/O Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, Ny 10010-3629 Date: August 7, 2019 To: Ironwood Pharmaceuticals, Inc. 301 Binney Street Cambridge, Ma 02142 Attn: Chief Legal Officer From: Credit Suisse Capital LLC Subject: Partial Terminations of Relevant Transactions Listed on Attached Schedule a and Related Amendments

from 8-K 33 pages The Purpose of This Letter Agreement (This “Confirmation”) Is to Confirm the Terms and Conditions of the Call Option Transaction Entered Into Between Credit Suisse Capital LLC (“Dealer”), Represented by Credit Suisse Securities (USA) LLC (“Agent”) and Ironwood Pharmaceuticals, Inc. (“Counterparty”) as of the Trade Date Specified Below (The “Transaction”). This Letter Agreement Constitutes a “Confirmation” as Referred to in the Isda Master Agreement Specified Below. This Confirmation Shall Replace Any Previous Agreements With Respect to the Transaction and Serve as the Final Documentation for the Transaction

from 8-K 33 pages The Purpose of This Letter Agreement (This “Confirmation”) Is to Confirm the Terms and Conditions of the Call Option Transaction Entered Into Between Credit Suisse Capital LLC (“Dealer”), Represented by Credit Suisse Securities (USA) LLC (“Agent”) and Ironwood Pharmaceuticals, Inc. (“Counterparty”) as of the Trade Date Specified Below (The “Transaction”). This Letter Agreement Constitutes a “Confirmation” as Referred to in the Isda Master Agreement Specified Below. This Confirmation Shall Replace Any Previous Agreements With Respect to the Transaction and Serve as the Final Documentation for the Transaction

from 10-Q 26 pages The Purpose of This Letter Agreement (This “Confirmation”) Is to Confirm the Terms and Conditions of the Warrants Issued by Ironwood Pharmaceutical, Inc. (“Company”) to Credit Suisse Capital LLC (“Dealer”), Represented by Credit Suisse Securities (USA) LLC (“Agent”) as Its Agent, as of the Trade Date Specified Below (The “Transaction”). This Letter Agreement Constitutes a “Confirmation” as Referred to in the Isda Master Agreement Specified Below. This Confirmation Shall Replace Any Previous Agreements With Respect to the Transaction and Serve as the Final Documentation for the Transaction

from 10-Q 27 pages The Purpose of This Letter Agreement (This “Confirmation”) Is to Confirm the Terms and Conditions of the Call Option Transaction Entered Into Between Credit Suisse Capital LLC (“Dealer”), Represented by Credit Suisse Securities (USA) LLC (“Agent”) as Its Agent, and Ironwood Pharmaceuticals, Inc. (“Counterparty”) as of the Trade Date Specified Below (The “Transaction”). This Letter Agreement Constitutes a “Confirmation” as Referred to in the Isda Master Agreement Specified Below. This Confirmation Shall Replace Any Previous Agreements With Respect to the Transaction and Serve as the Final Documentation for the Transaction

from 10-Q 25 pages The Purpose of This Letter Agreement (This “Confirmation”) Is to Confirm the Terms and Conditions of the Warrants Issued by Ironwood Pharmaceutical, Inc. (“Company”) to Credit Suisse Capital LLC (“Dealer”), Represented by Credit Suisse Securities (USA) LLC (“Agent”) as Its Agent, as of the Trade Date Specified Below (The “Transaction”). This Letter Agreement Constitutes a “Confirmation” as Referred to in the Isda Master Agreement Specified Below. This Confirmation Shall Replace Any Previous Agreements With Respect to the Transaction and Serve as the Final Documentation for the Transaction

from 10-Q 27 pages The Purpose of This Letter Agreement (This “Confirmation”) Is to Confirm the Terms and Conditions of the Call Option Transaction Entered Into Between Credit Suisse Capital LLC (“Dealer”), Represented by Credit Suisse Securities (USA) LLC (“Agent”) as Its Agent, and Ironwood Pharmaceuticals, Inc. (“Counterparty”) as of the Trade Date Specified Below (The “Transaction”). This Letter Agreement Constitutes a “Confirmation” as Referred to in the Isda Master Agreement Specified Below. This Confirmation Shall Replace Any Previous Agreements With Respect to the Transaction and Serve as the Final Documentation for the Transaction